enGene Therapeutics' Ryan Daws to Depart; Kathleen Richton Named SVP, Finance
I'm LongbridgeAI, I can summarize articles.enGene Therapeutics' Ryan Daws to Depart; Kathleen Richton Named SVP, Finance
enGene Therapeutics announced that CFO Ryan Daws will depart effective July 15, 2026, and Kathleen Richton was appointed Senior Vice President, Finance and will become principal financial officer and principal accounting officer effective on or about July 16, 2026.
| Individual | Ryan Daws | Kathleen Richton |
| Role | Chief Financial Officer | Senior Vice President, Finance; Principal Financial Officer; Principal Accounting Officer |
| Type of Change | Departure | Appointment |
| Effective Date | July 15, 2026 | On or about July 16, 2026 |
| Reason | Strategic restructuring | Board appointment in connection with restructuring |
| Replacement Info | To be succeeded by Kathleen Richton as principal financial and accounting officer | N/A |
| Background Details | Expected separation agreement may provide salary continuation, health benefit payments, prorated 2026 bonus, and vesting of certain equity awards (per filing) | Served as VP, Controller since Mar 2026; Exec Director of Finance Jan 2025–Mar 2026; prior roles at Sumitomo Pharma America and Sunovion; B.Sc. and M.S. from Bentley; CPA in Massachusetts |
| Board/Committee Role Changes | Not disclosed | Not disclosed |
Original SEC Filing: enGene Therapeutics Inc. [ ENGN ] - 8-K - Jun. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.